Voyager Therapeutics Inc (VYGR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $107.66M
Last updated: Nov 17, 2026 at 11:03 AM ET
Voyager Therapeutics Inc (VYGR) Stock Forecast
Analysts expect Voyager Therapeutics (VYGR) to earn -$1.65 per share in the fiscal year ending Dec 31, 2026, on revenue of $15.37M. Of 11 analysts, 11 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 11 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 191.1%.
- Fiscal year ending Dec 31, 2026
- -$1.65
- EPS consensus, revenue $15.37M
- Fiscal year ending Dec 31, 2027
- -$1.28
- EPS consensus, revenue $44.74M
- Next report
- Mar 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.65 | -$1.71 to -$1.58 | 6 | $15.37M | $12.80M to $24.77M | 9 |
| Dec 31, 2027 | -$1.28 | -$2.12 to -$0.51 | 10 | $44.74M | $7.00M to $122.93M | 11 |
Quarterly Estimates
The EPS consensus rises from -$0.42 for the quarter ending Dec 31, 2026 to -$0.40 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.42 | -$0.88 to -$0.08 | 13 | $8.43M | $2.94M to $29.93M | 13 |
| Mar 31, 2027 | -$0.40 | -$0.52 to -$0.26 | 5 | $5.62M | $2.50M to $11.80M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 8 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 0 |
| Fiscal year ending Dec 31, 2027 | 3 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.70.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.65 | -$1.70 | -$1.70 | -$1.70 | -$1.70 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.28 | -$1.28 | -$1.28 | -$1.28 | -$1.28 | N/A |
| Quarter ending Mar 31, 2027 | -$0.40 | -$0.38 | -$0.38 | -$0.38 | -$0.41 | N/A |
Frequently Asked Questions About VYGR
What is the VYGR stock forecast?
Consensus analyst estimates put Voyager Therapeutics's EPS at -$1.65 for the fiscal year ending Dec 31, 2026, on revenue of $15.37M. The consensus rating from 11 analysts is Buy.
How do analysts rate VYGR stock?
Of 11 analysts covering Voyager Therapeutics, 0 rate it Strong Buy, 11 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from VYGR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.65, with estimates from -$1.71 to -$1.58 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.28, with estimates from -$2.12 to -$0.51 from 10 analysts.
What revenue do analysts expect from Voyager Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $15.37M, with estimates from $12.80M to $24.77M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $44.74M, with estimates from $7.00M to $122.93M.
How many analysts cover VYGR?
11 analysts rate Voyager Therapeutics stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
VYGR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors